Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 4Recurrence 2Infections 1

Interventions

Surgical Procedures, Operative 7Liver Transplantation 5Lenalidomide 4Blood Specimen Collection 4pomalidomide 3Neoadjuvant Therapy 3Liquid Biopsy 3gilteritinib 2Therapeutics 2Rituximab 2Proteasome Inhibitors 2Observation 2Mohs Surgery 2Mitomycin 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Immunoconjugates 2High-Throughput Nucleotide Sequencing 2Fluorouracil 2Drug Therapy 2DNA, Mitochondrial 2Brentuximab Vedotin 2Bendamustine Hydrochloride 2Antibodies, Monoclonal 2Antibodies, Bispecific 2Amplified Fragment Length Polymorphism Analysis 2trametinib 1romidepsin 1nedaplatin 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Recurrence × gilteritinib × Clear all
NCT06734585 2025-09-12

Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

Astellas Pharma Inc

Completed
114 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04691648 2025-05-31

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Astellas Pharma Inc

Completed
33 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡